alere tm hiv combo

7
www.aids2014.org Evaluation of new rapid fourth generation point of care test device for the early diagnosis of HIV infection Alere TM HIV Combo Yuko Tamanoue, Product Development Department

Upload: unity-ballard

Post on 31-Dec-2015

74 views

Category:

Documents


0 download

DESCRIPTION

Evaluation of new rapid fourth generation point of care test device for the early diagnosis of HIV infection. Alere TM HIV Combo. Yuko Tamanoue, Product Development Department. Alere™ HIV Combo- Rationale. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Alere TM  HIV Combo

www.aids2014.org

Evaluation of new rapid fourth generation point of care test device for the early diagnosis of HIV infection

AlereTM HIV Combo

Yuko Tamanoue, Product Development Department

Page 2: Alere TM  HIV Combo

www.aids2014.org

Alere™ HIV Combo- Rationale

• Acute infection accounts for 5-20% of all cases of HIV infection among person seeking testing.

• The seroconversion window period is associated with peak levels of viremia and high risk of transmission

• Earlier identification would:– Increase case finding– Facilitate earlier referral to care– Earlier Treatment– Partner Notification

Page 3: Alere TM  HIV Combo

www.aids2014.org

Seroconversion Panels19 panels 3rd generation

rapid test (Ab)

FDA- approved HIV 4th generation

(Ag/Ab)

HIV EIA Ag (Ag)

Alere HIV Combo (Ag/Ab)

Earlier 16 0 2

Same 3 9 10

Later 0 2 0

Total panels 19 11 12

PCR

↓ ↓ ↓

Day -5.3 -0.6 0↑ ↑ Ag EIA

Alere HIVCombo

3rdgeneration

FDA approved4th generation

+6.7+0.6

Page 4: Alere TM  HIV Combo

www.aids2014.org

Acute HIV infection

RNAFDA- approved

HIV 4th generation (Ag/Ab)

Alere HIV ComboNo. of positive samples

  Judge S/CO No. of positive Judge Ab Ag %

P N <1 3 N 17 17 NA

  P 1~<5 18 P 1 5 33.3%

  P 5~<10 10 P 0 8 80.0%

  P 10~<20 8 P 0 8 100.0%

  P 20~<50 15 P 2* 15 100.0%

  P 50~621 15 P 3* 15 100.0%

69  Positive  66 Positive 52 78.8%* Both Ag/Ab positive

Page 5: Alere TM  HIV Combo

www.aids2014.org

Analytical sensitivity of HIV-1 p24 and subtype detection

• Analytical sensitivity of HIV-1 p24: 2 IU/ml• HIV-1 antibody subtype panels:

100% (40/40),

A, B, C, D, CRF01-AE, CRF02-AG, F, G, H, J, K, O

• HIV-1 virus subtype panel for antigen:

100% (31/31)

A, B, C, D, CRF01-AE, CRF02-AG, F, G, H, O

Page 6: Alere TM  HIV Combo

www.aids2014.org

Specificity

SampleSample

No.

Alere HIV ComboNo. of positive

  Ab Ag

HIV negative specimens (US) 1099 0 1

HIV negative specimens (Africa) 150 0 0

Disease state other than HIV and potentially interfering substances 346 0 0

Total 1595 0 1

  Specificity  99.9%

Page 7: Alere TM  HIV Combo

www.aids2014.org

Conclusions

• Alere™ HIV Combo shows comparable performance to FDA-approved 4th generation laboratory assay

• Alere™ HIV Combo shows marked improvement in case finding over 3rd generation poc test

• Alere™ HIV Combo could be a useful diagnostic tool in HIV screening programmes worldwide